Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.eururo.2014.08.065 | DOI Listing |
J Biophotonics
May 2023
The Photon Factory, University of Auckland, Auckland, New Zealand.
Prostate cancer (PCa) is a significant healthcare problem worldwide. Current diagnosis and treatment methods are limited by a lack of precise in vivo tissue analysis methods. Real-time cancer identification and grading could dramatically improve current protocols.
View Article and Find Full Text PDFEur Urol Oncol
August 2021
Department of Urologic Oncology, NYU Langone Medical Center, New York, NY, USA.
Context: The diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) for prostate cancer (PCa) diagnosis has been extensively explored. Little is known about the prognostic value of mpMRI suspicion scores and other quantitative mpMRI information.
Objective: To systematically review the current literature assessing the relationship between pretreatment mpMRI and oncological outcomes after primary treatment for PCa to assess the role of mpMRI as a prognostic tool.
Eur Urol
September 2019
Wesley Hospital, Brisbane, Australia.
Eur Urol
October 2019
Department of Medicine, University of Queensland, Brisbane, Australia; Wesley Urology Clinic, Brisbane, Australia.
Purpose: To review our experience with MRI-guided in-bore prostate biopsy (MRGB) and present a review of the literature on MRGB.
Methods: A retrospective review of patients presenting for MRGB between 2013 and 2018. Diagnostic and biopsy MRI scans were reviewed to collect data on scan dates, procedure times, characteristics of MRI targets (PI-RADS™ score, target size, ADC value and location).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!